Mar 24, 2023 / 12:00PM GMT
Operator
Greetings. Welcome to the Celyad Oncology full-year 2022 earnings conference call. (Operator Instructions) Please note that this conference is being recorded.
At this time, I'll now turn the conference over to David Georges, Vice President, Finance and Administration. David, you may now begin.
David Georges - Celyad Oncology SA - VP of Finance & Administration
Thank you, operator. Thank you all for joining us today. Before we begin, I would like to remind everyone that today's event may contain forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may involve known and unknown risks and uncertainties, which might cause actual results, financial condition, performance, or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
A list and description of these risks, uncertainties and other risks can be found in the company's US Securities and Exchange
Q4 2022 Celyad Oncology SA Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot